title: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
abstract: OBJECTIVE
  Ornipressin, a vasopressin analog with potent splanchnic vasoconstrictor action, has been shown to reverse hepatorenal syndrome. However, its usefulness in clinical practice is limited by frequent ischemic complications. The aim of this study was to assess the efficacy of terlipressin, an analog of vasopressin with a low profile of side effects, plus albumin in this condition.
  
  
  METHODS
  Nine consecutive patients with cirrhosis and hepatorenal syndrome were included in a pilot study of terlipressin (0.5-2 mg/4 h i.v.) therapy associated with iv albumin.
  
  
  RESULTS
  Treatment (9 days, range 5-15) was associated with a marked reduction of serum creatinine (3.9+/-0.7 to 1.3+/-0.1 mg/dl, p<0.001, mean+/-SE). Reversal of hepatorenal syndrome (reduction of creatinine below 1.5 mg/dl) was observed in seven of the nine patients. There was a remarkable improvement in circulatory function, with an increase in mean arterial pressure (68+/-2 to 80+/-4 mmHg, p<0.05) and suppression of vasoconstrictor systems activity (plasma renin activity and plasma norepinephrine decreased from 23+/-12 ng/ml x h and 1549+/-373 pg/ml to 3.5+/-2 ng/ml x h and 373+/-98 pg/ml, respectively, p<0.01 for both). No patient developed signs of intestinal, myocardial or distal ischemia.
  
  
  CONCLUSIONS
  Terlipressin associated with albumin appears to be a safe and effective treatment of hepatorenal syndrome.
authors.affiliation: Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi-Sunyer, Catalunya, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Uriz
authors.forename: P
authors.initials: P
authors.lastname: Ginès
authors.forename: A
authors.initials: A
authors.lastname: Cárdenas
authors.forename: P
authors.initials: P
authors.lastname: Sort
authors.forename: W
authors.initials: W
authors.lastname: Jiménez
authors.forename: J M
authors.initials: JM
authors.lastname: Salmerón
authors.forename: R
authors.initials: R
authors.lastname: Bataller
authors.forename: A
authors.initials: A
authors.lastname: Mas
authors.forename: M
authors.initials: M
authors.lastname: Navasa
authors.forename: V
authors.initials: V
authors.lastname: Arroyo
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006530:Hepatorenal Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010865:Pilot Projects; D012083:Renin / Q000097:blood; D012709:Serum Albumin / Q000627:therapeutic use*; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D012709:Serum Albumin; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D003404:Creatinine; D012083:Renin; D009638:Norepinephrine